Stockscreener 앱 받기
98.99
0.76%
-0.76
시간 외 거래:
98.00
-0.99
-1.00%
전일 마감가:
$99.75
열려 있는:
$99.82
하루 거래량:
1.68M
Relative Volume:
1.06
시가총액:
$19.78B
수익:
$5.36B
순이익/손실:
$1.43B
주가수익비율:
14.00
EPS:
7.0718
순현금흐름:
$1.42B
1주 성능:
-6.07%
1개월 성능:
+3.86%
6개월 성능:
+1.39%
1년 성능:
+43.86%
1일 변동 폭
$98.25
$101.03
1주일 범위
$98.25
$109.69
52주 변동 폭
$66.74
$112.29
인사이트 코퍼레이션 Stock (INCY) Company Profile
명칭
Incyte Corp
전화
(302) 498-6700
주소
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
98.99 | 20.37B | 5.36B | 1.43B | 1.42B | 7.0718 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
인사이트 코퍼레이션 Stock (INCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2026-02-05 | 개시 | H.C. Wainwright | Buy |
| 2026-01-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-11-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-10-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | 개시 | Barclays | Overweight |
| 2025-06-16 | 업그레이드 | Stifel | Hold → Buy |
| 2025-03-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-18 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 개시 | UBS | Neutral |
| 2024-10-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-01 | 개시 | Wolfe Research | Outperform |
| 2024-09-18 | 다운그레이드 | Truist | Buy → Hold |
| 2024-07-02 | 다운그레이드 | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 개시 | Deutsche Bank | Hold |
| 2024-04-23 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 개시 | Jefferies | Buy |
| 2024-02-14 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-11-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-25 | 개시 | Citigroup | Buy |
| 2023-05-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-04-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 개시 | Piper Sandler | Overweight |
| 2022-08-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-07-28 | 개시 | Wells Fargo | Equal Weight |
| 2022-02-09 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-07-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-02-10 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 개시 | Truist | Buy |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-06-16 | 개시 | The Benchmark Company | Hold |
| 2020-05-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 재개 | William Blair | Outperform |
| 2020-03-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 재개 | BofA/Merrill | Neutral |
| 2020-01-03 | 재확인 | BMO Capital Markets | Market Perform |
| 2020-01-03 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-10-03 | 개시 | Mizuho | Buy |
| 2019-09-12 | 개시 | BMO Capital Markets | Market Perform |
| 2019-09-05 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 개시 | Credit Suisse | Neutral |
| 2019-05-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 개시 | Stifel | Hold |
| 2019-04-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | 업그레이드 | William Blair | Mkt Perform → Outperform |
모두보기
인사이트 코퍼레이션 주식(INCY)의 최신 뉴스
Incyte slides as investors digest updated INCA033989 (mutCALR) data and a cautious analyst take - Quiver Quantitative
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
BMO reiterates Incyte stock Underperform on ET/MF trial data - Investing.com UK
Key deals this week: GSK, Incyte, Ingredion, OpenAI, and more - MSN
BMO reiterates Incyte stock Underperform on ET/MF trial data By Investing.com - Investing.com Canada
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review - Yahoo Finance
Stifel reiterates Incyte stock rating on drug trial data review - Investing.com
Stifel reiterates Incyte stock rating on drug trial data review By Investing.com - Investing.com Canada
Incyte nears $2B deal for blood disorder drug developer Star Therapeutics: FT - MSN
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival - BioSpace
Incyte (INCY) Reports Promising Phase 2 Results for Zilurgiserti - GuruFocus
Incyte (INCY) Shows Promising Phase 3 Trial Results for Tafasita - GuruFocus
Incyte (INCY) Reveals Promising Results for Novel Antibody in Cl - GuruFocus
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva - Yahoo Finance Singapore
Key deals this week: GSK, Incyte, Ingredion, OpenAI, and more (BCS:NYSE) - Seeking Alpha
Incyte to buy Vega Therapeutics in hematology deal worth up to $2B - MSN
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia - Business Wire
Incyte Stock (US45337C1027): Ownership shifts and pipeline focus keep shares in view - AD HOC NEWS
Lymphoma drug combo cut risk of progression or death 25% - Stock Titan
Incyte reports positive Phase 3 trial results for lymphoma drug - Investing.com
Rx Rundown: Incyte, Parabilis Medicines, Pfizer and more - Medical Marketing and Media
Incyte Stock (US45337C1027): Quarterly trends and sector context for US investors - AD HOC NEWS
Incyte Buys Vega To Add Late Stage Von Willebrand Disease Opportunity - Yahoo Finance
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte Nears Buy Point As $1.25 Billion Acquisition Expands Offerings - Investor's Business Daily
Incyte Corporation $INCY Shares Bought by Illinois Municipal Retirement Fund - MarketBeat
Incyte bolsters haematology portfolio in $2bn Vega buyout - MSN
Incyte Buyout Bet: The $2 Billion Move Investors Can’t Ignore! - Smartkarma
Daily Brief Health Care: Laurus Labs, Ascendis Pharma, GSK , Incyte Corp, Insmed Inc, Johnson & Johnson, Kardigan, LogicMark, Parabilis Medicines, Solventum and more - Smartkarma
Incyte to Acquire Vega Therapeutics from Star Therapeutics for Up to $2 Billion - Global Legal Chronicle
Why Incyte (INCY) Stock Is Up Today - Yahoo Finance
Incyte (INCY) director Jacqualyn Fouse awarded RSUs and 6,111 stock options - Stock Titan
H.C. Wainwright raises Incyte stock price target to $140 on Vega deal - Investing.com
Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2B - Yahoo Finance
INCY Maintains Rating by HC Wainwright & Co. -- Price Target Rai - GuruFocus
Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster PotentialIncyte (NASDAQ:INCY - Benzinga
HC Wainwright Issues Positive Forecast for Incyte (NASDAQ:INCY) Stock Price - MarketBeat
Incyte to acquire blood disorder drug candidate for $2B - Delaware Business Times
Stifel reiterates Incyte stock Buy rating on VGA039 acquisition - Investing.com
Stifel reiterates Incyte stock Buy rating on VGA039 acquisition By Investing.com - Investing.com UK
Incyte Corp at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Natixis Advisors LLC Purchases 10,795 Shares of Incyte Corporation $INCY - MarketBeat
Incyte Corporation (INCY) Announces Acquisition of Vega Therapeu - GuruFocus
Incyte makes $2 billion bet on bleeding disorder drug ahead of Jakafi patent cliff - MSN
In its largest M&A deal, Incyte adds late-stage bleeding candidate via Vega buy - BioCentury
Goodwin, Fenwick Guide Incyte-Vega Deal Worth Up To $2B - Law360
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Three Bay Area biotech startups ink big-company deals potentially totaling $5 billion - The Business Journals
Oppenheimer raises Incyte stock price target on Vega acquisition By Investing.com - Investing.com Australia
Oppenheimer raises Incyte stock price target on Vega acquisition - Investing.com
Incyte To Acquire Vega Therapeutics For Up To $2 Billion To Expand Hematology Portfolio Into Bleeding Disorders - Pulse 2.0
인사이트 코퍼레이션 (INCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
인사이트 코퍼레이션 주식 (INCY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Tray Thomas | Principal Accounting Officer |
Jun 04 '26 |
Sale |
100.00 |
2,639 |
263,900 |
21,132 |
2.60%
0.94%
자본화:
|
볼륨(24시간):